Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.79 |
| ▸ | BRD2 | P25440 | 1/20 | 0.47 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.47 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.47 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | BRWD1 | Q9NSI6 | 1/20 | 0.47 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15329043 | 0.89 | BRD4 (1.00) | BRD4BRD2SMARCA2BRD3BRDT | |
| SCHEMBL15328497 | 0.87 | BRD4 (1.00) | BRD4BRD2SMARCA2BRD3BRDT | |
| SCHEMBL15328950 | 0.86 | BRD4 (0.78) | BRD4BRD2SMARCA2BRD3BRDT | |
| SCHEMBL15328747 | 0.85 | BRD4 (1.00) | BRD4BRD2SMARCA2BRD3BRDT | |
| SCHEMBL15328786 | 0.83 | BRD4 (0.79) | BRD4BRD2SMARCA2BRD3BRDT | |
| SCHEMBL15328550 | 0.79 | BRD4 (1.00) | BRD4BRD2SMARCA2BRD3BRDT | |
| SCHEMBL15328761 | 0.74 | BRD4 (1.00) | BRD4BRD2SMARCA2BRD3BRDT | |
| SCHEMBL16008012 | 0.74 | BRD4 (0.77) | BRD4BRD2SMARCA2BRD3BRDT | |
| SCHEMBL15328814 | 0.74 | BRD4 (1.00) | BRD4BRD2SMARCA2BRD3BRDT | |
| SCHEMBL15328624 | 0.72 | BRD4 (1.00) | BRD4BRD2SMARCA2BRD3BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838881-B1 | ISOINDOLONE DERIVATIVES | ABBVIE INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-9776990-B2 | Isoindolone derivatives | ABBVIE INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150111890-A1 | ISOINDOLONE DERIVATIVES | ABBVIE INC. | 2015-04-23 | — | — | US | disclosed |
| EP-2850071-A1 | ISOINDOLONE DERIVATIVES | AbbVie Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| EP-2838881-A1 | ISOINDOLONE DERIVATIVES | AbbVie Inc. (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013155695-A1 | ISOINDOLONE DERIVATIVES | ABBOTT LABORATORIES (US) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013158952-A1 | ISOINDOLONE DERIVATIVES | ABBVIE INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281450-A1 | ISOINDOLONE DERIVATIVES | ABBVIE INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111890-A1 | ISOINDOLONE DERIVATIVES | CYP11B1, HSD17B7, CYP4A11 | BRD4 2626/4885BRD2 3083/4885SMARCA2 2016/4885 |
| US-20130281450-A1 | ISOINDOLONE DERIVATIVES | CYP11B1, HSD17B7, CYP4A11 | BRD4 2624/4885BRD2 3113/4885SMARCA2 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.